The structure of MDCC-labeled Hsp90α MD and CTD reported here provides the first direct visual insight into allosteric binding inhibitors of Hsp90 MD or CTD and provides a basis for the design of novel drugs for the treatment of cancer and neurodegenerative diseases. Here, HSP90AB1 is linked to neurodegenerative disease.